Contents
THE EUROPEAN COMMISSION,Having regard to the Treaty on the Functioning of the European Union,Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal productsnote, and in particular the third subparagraph of Article 89(1) thereof,Whereas:
(1)Commission Delegated Regulation (EU) No 1062/2014note establishes a list of existing active substances to be evaluated for their possible approval for use in biocidal products. That list includes didecyldimethylammonium chloride.
(2)Didecyldimethylammonium chloride has been evaluated for use in biocidal products of product-type 1 (human hygiene biocidal products) and product-type 2 (private area and public health area disinfectants and other biocidal products), as defined in Annex V to Directive 98/8/EC of the European Parliament and of the Councilnote, which correspond respectively to product-types 1 and 2 as described in Annex V to Regulation (EU) No 528/2012.
(3)Italy was designated as the rapporteur Member State and its evaluating competent authority submitted the assessment report together with its conclusions to the Commission on 10 September 2012. After the submission of the assessment report, discussions took place in technical meetings organised by the European Chemicals Agency (‘the Agency’).
(4)It follows from Article 90(2) of Regulation (EU) No 528/2012 that substances for which the Member States’ evaluation has been completed by 1 September 2013 are to be evaluated in accordance with the provisions of Directive 98/8/EC.
(5)In accordance with Article 75(1) of Regulation (EU) No 528/2012, the Biocidal Products Committee prepares the opinion of the Agency regarding the applications for approval of active substances. In accordance with Article 7(2) of Delegated Regulation (EU) No 1062/2014, the Biocidal Products Committee adopted the opinions of the Agencynote on 2 December 2021, having regard to the conclusions of the evaluating competent authority.
(6)According to those opinions biocidal products of product-types 1 and 2 containing didecyldimethylammonium chloride may be expected to satisfy the requirements laid down in Article 5(1), points (b), (c) and (d), read in conjunction with Article 10(1) of Directive 98/8/EC, provided that certain requirements concerning their use are complied with.
(7)Taking into account the opinions of the Agency, it is appropriate to approve didecyldimethylammonium chloride as an active substance for use in biocidal products of product-types 1 and 2 subject to compliance with certain conditions.
(8)A reasonable period should be allowed to elapse before an active substance is approved in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.
(9)The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,
HAS ADOPTED THIS REGULATION:
Article 1#
Didecyldimethylammonium chloride is approved as an active substance for use in biocidal products of product-types 1 and 2 subject to the conditions set out in the Annex.
Article 2#
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
| Common Name | IUPAC NameIdentification Numbers | Minimum degree of purity of the active substancenote | Date of approval | Expiry date of approval | Product type | Specific conditions |
|---|---|---|---|---|---|---|
| Didecyldimethylammonium chloride | IUPAC name: N,N-Didecyl-N,N-dimethylammonium chlorideEC No: 230-525-2CAS No: 7173-51-5 | 908 g/kg dry weight | 1 February 2024 | 31 January 2034 | 1 | The authorisation of biocidal products is subject to the following condition:The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. |
| 2 | The authorisation of biocidal products is subject to the following conditions:1. The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.2. The product assessment shall pay particular attention to the exposure and potential risks for professional users. |
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.